Mr. Glenn Schulman reports

AURINIA PHARMACEUTICALS TO RELEASE FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS ON MARCH 19, 2019

Aurinia Pharmaceuticals Inc. will release its fourth quarter and full-year 2018 financial results on Tuesday, March 19, 2019, after the market closes. Aurinia's management team will host a conference call to discuss the company's financial results for the fourth quarter and full-year 2018 and to provide a general business update.

The conference call and webcast are scheduled for March 19, 2019, at 4:30 p.m. ET. In order to participate in the conference call, please dial 1-877-407-9170 (toll-free United States and Canada). An audio webcast can be accessed under "news/events" through the investors section of the Aurinia corporate website. A replay of the webcast will be available on Aurinia's website.

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals is a late-clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations impacted by serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS) and dry eye syndrome (DES). The company is headquartered in Victoria, B.C., and focuses its development efforts globally.